Details

Autor(en) / Beteiligte

• Thompson, Elizabeth A.
• Darrah, Patricia A.
• Foulds, Kathryn E.
• Hoffer, Elena
• Caffrey-Carr, Alayna
• Norenstedt, Sophie
• Perbeck, Leif
• Seder, Robert A.
• Kedl, Ross M.
• Loré, Karin

Titel

Monocytes Acquire the Ability to Prime Tissue-Resident T Cells via IL-10-Mediated TGF-β Release

Ist Teil von

• Cell reports (Cambridge), 2019-07, Vol.28 (5), p.1127-1135.e4

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2019

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Using non-human primates (NHPs), mice, and human primary cells, we found a role for interleukin-10 (IL-10) in the upregulation of the tissue-resident memory T cell (TRM) marker CD103. In NHPs, intravenous, but not subcutaneous, immunization with peptide antigen and an adjuvant combining an agonistic anti-CD40 antibody plus poly(IC:LC) induced high levels of CD103+ TRMs in the lung, which correlated with early plasma IL-10 levels. Blocking IL-10 reduced CD103 expression on human T cells stimulated in vitro with the adjuvant combination as well as diminished CD103 on lung-resident T cells in vivo in mice. Monocyte-produced IL-10 induced the release of surface-bound transforming growth factor β (TGF-β), which in turn upregulated CD103 on T cells. Early TGF-β imprinted increased sensitivity to TGF-β restimulation, indicating an early commitment of the T cell lineage toward TRMs during the priming stage of activation. IL-10-mediated TGF-β signaling may therefore have a critical role in the generation of TRM following vaccination. [Display omitted] •Intravenous administration of an agonistic anti-CD40 antibody induces early IL-10•IL-10 levels in the plasma correlate with CD103+ TRMs in the lung•Blocking IL-10 in vitro or in vivo reduces CD103+ TRMs•Monocyte-derived IL-10 induces TGF-β release and CD103 upregulation on naive T cells Thompson et al. outline a role for early IL-10 following immunization in the release of TGF-β and subsequent differentiation of CD103+ TRMs. Using a combination of non-human primate, human, and murine systems, the authors demonstrate that blocking IL-10 reduces CD103 expression, whereas delivery of IL-10 can augment a CD103+ phenotype.